#ASH25: Novartis says its antibody ianalumab helps prolong control of rare blood disorder

Novartis said its latest experimental approach for a rare blood disorder prolonged patients’ disease control by 45% compared to a placebo arm. The Phase 3 results, which follow a topline readout in ...